In Law360, Matt Byron Discussed 2026 Dealmaking Outlook at J.P. Morgan Healthcare Conference

In a Law360 article, mergers & acquisitions partner Matt Byron discussed the healthcare dealmaking outlook at the 2026 J.P. Morgan Healthcare Conference.

For large pharmaceutical companies "they're still being very thoughtful and critical in terms of how they approach their investments. That means the industry is likely to see a continuation of spinoff deals and single-asset transactions this year,” said Matt.

“There's a lot of platform companies out there, biotech companies that have a number of programs that are expensive to develop, and Big Pharma isn't buying the whole company,” he said.